Targeting microbial dysbiosis in Food Allergy to restore tolerance
- Institution
- BOSTON CHILDREN'S HOSPITAL, MA
- Principal investigator
- Talal Amine Chatila
- Funding
- $584K
- Duration
- 2021–2026
Moonbase score
Still being scored
Abstract
ABSTRACT Food allergy (FA) has become a public health concern, affecting a sizeable segment of the population. Despite the alarming increase in its prevalence, efforts to contain the FA epidemic have been stymied by the limited understanding of disease pathogenesis, especially the role in this process of early life gut dysbiosis. In that regard, our studies have established a critical role for immunomodulatory Clostridiales and Bacteroidales species in enforcing immune tolerance to FA by inducing the differentiation of RORgt+ Treg cells, which act to suppress FA. Early life expansion of RORgt+ Treg cells is induced by the bloom in Clostridiales and Bacteroidales species during weaning from maternal milk to solid food. This expansion is counter-regulated by resistin-like molecule beta (RELMb), which is elevated in FA subjects and mice. Accordingly, the focus of this proposal is to elucidate the mechanisms by which early life dysbiosis promotes FA and its long-term implications in terms of disease persistence and response to microbial therapy. We hypothesize that the microbial and immunological changes ushered by weaning early in life provide a window of opportunity for tolerance induction to solid food in a process regulated by RELMb, whose dysregulation by dysbiosis promotes FA (Aim 1). We also hypothesize that the ineffective differentiation of RORgt+ Treg cell populations and the reciprocal emergence of Th2 cell-like Treg cells, an imbalance we have identified to play a fundamental role in FA, acts to promote disease pathogenesis by licensing IgE anti-food and anti-bacterial antibody responses (Aim 2). Finally, we hypothesize that products and metabolites of individual immunomodulatory bacterial strains, including Toll-like receptors activators, aryl hydrocarbon receptor ligands and secondary bile acids, act to enforce oral tolerance in FA by promoting RORgt+ Treg cell differentiation (Aim 3). The proposed studies will provide fundamental new insights relevant to the pathogenesis of FA and offers novel opportunities in early life disease intervention and therapy.
Research team
- Talal Amine ChatilaPI
- Seth Rakoff-NahoumPI
LOADING MOONBASE SCORE
Questions for BOSTON CHILDREN'S HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Boston University (Charles River Campus)Not yet scored
Programmable benchtop bioreactors for scalable eco-evolutionary dynamics of the human microbiome
Ahmad Samir Khalil · $1.6M · 2022–2027
- NIH · Boston Children'S HospitalNot yet scored
Immunological and Microbial Mechanisms in Food Allergy
Talal Amine Chatila · $609K · 2016–2028
- NIH · Boston Children'S HospitalNot yet scored
Genetic and Epigenetic Programming of Allergic Airway Inflammation
Talal Amine Chatila · $653K · 1998–2028